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Several studies have identified the importance of pro-inflammatory mediators in the development and 
progression of cardiac disease such as heart failure (HF). Recently, a number of studies from basic research 
have used gene expression, array screening, cloning, and other techniques to identify new cardiokines and 
cardiokine networks that are regulated during cardiac stress. IL-33, an IL-1 family member, binds to a ST2L, 
which is a member of the Toll-like receptor (TLR)/IL1R superfamily. Besides ST2L, the ST2 gene can encode 
two other isoforms by alternative splicing, including a secreted soluble ST2 (sST2) form that could act as a 
decoy receptor for IL-33. Studies in animal models suggest that IL-33/ST2 is involved in cardiovascular disease 
and plays an important role in protection of cardiac muscle. Furthermore, sST2 is a promising biomarker 
predictive of worse outcome in several cardiovascular diseases. Although manipulation of IL-33/ST2 system is 
still in its infancy, it may be a unique opportunity to quench the inflammatory response after cardiac injury.  
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 Introduction  
Inflammation has emerged as a crucial process that plays 
a role in cardiovascular disease [1]. Several studies have 
identified the importance of pro-inflammatory mediators in 
the development and progression of cardiac disease such as 
heart failure (HF) [2-4]. These factors can induce myocardial 
remodeling either by promoting the recruitment of 
inflammatory cells or by producing maladaptive effects in 
the heart, such as left ventricle (LV) remodeling and 
endothelial dysfunction, thus facilitating hypertrophy and 
fibrosis [5]. However, anti-inflammatory therapeutic 
strategies tested so far have been largely disappointing, due 
to either neutral results either worsening of HF. These 
findings have triggered important considerations, including 
the relevance of looking for novel targets [6]. 
Recently, a number of studies from basic research have 
used gene expression, array screening, cloning, and other 
techniques to identify new cardiokines and cardiokine 
networks that are regulated during cardiac stress [4]. With 
genetic animal models, many of these newly identified 
molecules have been shown to have functional roles in 
cardiac remodeling. 
In this review we will focus on recent research related to 
the cardiovascular role of the IL-33/ST2 pathway, 
including the translational aspect. The potential of using 
IL-33 or its receptor ST2 for therapeutic intervention of 
cardiovascular disease will also be discussed. Finally, the 
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role of soluble ST2 as a potential biomarker for 
cardiovascular disease will be debated. 
 1. IL-33/ST2 pathway 
a. IL-33 identification, expression and activation  
Interleukin (IL)-33 (also known as IL-1F11) was 
initially identified as DVS27, a gene up-regulated in canine 
cerebral vasospasm [7], and as a “nuclear factor from high 
endothelial venules” (NF-HEV) [8]. In 2005, analysis of 
computational structural databases showed that this 
cytokine had a high homology to IL-18, and a β-sheet 
trefoil fold structure characteristic of IL-1 family proteins 
[9]. 
The human and mouse sequences for IL-33 have been 
localized to chromosomes 9 (9p24.1) and 19 (19qc1), 
coding proteins of 270 and 266 amino acids, respectively 
(Fig. 1). The 30 kDa molecule has high homology to IL-18 
(Fig. 1) [9]. IL-33 is a protein with a double role, acting as a 
traditional cytokine as well as a nuclear factor with 
transcriptional properties, although its physiological role is 
not fully clear [10]. 
IL-33 is present in many tissues, but its expression is 
greatest in stomach, lung, spinal cord, brain, and skin and 
low in lymph tissue, spleen, pancreas, kidney, and heart [9]. 
Some controversy exists regarding IL-33 biologically 
active form. During necrosis, the full-length IL-33, 
considered the biologically active form, may be released 
from injured cells. Conversely during apoptosis, IL-33 is 
cleaved by caspases-3/7 producing an inhibition of its pro-
inflammatory effects. These data suggest that full-length 
IL-33 may act as an endogenous danger signal or alarmin, 
while inactivation of IL-33 may be needed as a fail-safe 
control mechanism to avoid further impairment of host
Figure 1. Genomic regions, transcripts, and products of IL-33 (A) and ST2 (B). Human IL-33 gene is located on chromosome     
9, ST2 gene on chromosome 2. Figures were built up by Sequence Viewer 3.1 available at http://www.ncbi.nlm.nih.gov/gene/ (Green 
bar: gene; blue bar: RNA transcripts; red bar: coding region).  
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tissues by the IL-33 pro-inflammatory effect during 
apoptosis [10-11] (Fig. 2). 
b. IL-33 signaling by ST2 
The gene called ST2 (also known as T1, IL1RL1, or Fit1) 
was discovered in 1989 and is mapped on chromosome 
2q12 together with the wider interleukin 1 (IL-1) gene 
cluster [12]. Alternative splicing of gene promoter and 3' 
processing of the same mRNA produce four transcriptional 
products. Of these, two are the most important isoforms: 
IL1RL1-β or ST2L, a membrane receptor member of the 
interleukin-1 receptor family, and IL1RL1-α or sST2, a 
truncated soluble receptor that could be measured in 
peripheral circulation (Fig. 1B). ST2 gene has a proximal 
and a distal promoter, which could modify its 
transcriptional regulation [13]. ST2L is composed of three 
extracellular immunoglobulin G domains, a single trans-
membrane domain, and an intracellular domain [9, 12, 14]. The 
sST2 lacks the trans-membrane and intracellular domains 
and it moves freely through the peripheral circulation.  
IL-33 has been recognized as a functional ligand of 
ST2L [9, 14] and it binds ST2L on inflammatory cell 
membranes. This binding activates mitogen-activated 
protein kinase (MAPK)-kinases as well as several 
Figure 2. Production and signaling of IL-33/ST2 pathway. The full length IL-
33, considered the biologically active form, may be produced during necrosis. 
Conversely, IL-33 is cleaved by caspases-3/7 producing an inactive form during 
apoptosis. Active IL-33 can stimulate the formation of the heterodimeric 
ST2L/IL-1RAcP complex on the target cells or can be inhibited by sST2 that 
acts as a decoy receptor. Upon the activation of this complex, the signaling is 
induced. The MyD88, IRAK1/4 and TRAF-6 are localized to the receptor 
complex, leading to activation of transcription factors as NF-kB, p38 and JNK, 
as well as ERK (directly by MyD88). This leads to transcription of inflammatory 
genes. 
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biochemical pathways that lead the activation of the 
inhibitor of nucler factor-κB (NF-κB) kinase (IKK) 
complex, which activates NF-kB to exert its pro-
inflammatory actions [15]. Moreover, sST2 appears to act as 
a decoy-receptor for IL-33: it binds IL-33, consequently 
removing this protein from its possible binding with ST2L. 
sST2 binding with IL-33 could limit the expression and 
activation of NF-kB, thus reducing the inflammatory 
response (Fig. 2). IL-33 has been supposed to regulate the 
ST2L and sST2 mRNA transcription by itself [15, 16].     
2. Cardiac role of IL-33/ST2 pathway 
a. Cellular models 
The involvement of ST2 in cardiac compartment was 
initially suggested by Weinberg et al. in a screen of gene 
transcripts expressed by mechanically stressed car- 
diomyocytes in an in vitro model [17]. They found that both 
sST2 and ST2L are induced in cardiomyocytes and 
fibroblasts after biomechanical stress [17, 18].  
IL-33 and its receptor ST2 show distinct expression 
patterns in the heart. IL-33 is expressed by human adult 
cardiac myocytes and fibroblasts and by human coronary 
artery smooth muscle cells, while ST2 is predominantly 
expressed by endothelial cells of the cardiac vasculature. 
IL-33 is upregulated by TNF-α, IFN-γ and IL-1β and is 
released during necrosis of human cardiac and smooth 
muscle cells [19] (Fig. 3).  
b. Animal models 
The discovery of IL-33 as a ligand for ST2 has led to 
exploration of the role of IL-33/ST2 signaling in the 
myocardium. Thus, following its binding with ST2L, IL-33 
has been shown to have anti-hypertrophic and antifibrotic 
effects in the heart. In an in vitro rodent model of 
cardiomyocytes undergoing stretching, a direct relationship 
between duration of biomechanical strain and IL-33 and 
ST2 expression was observed [17]. Furthermore, 
administration of sST2, the soluble form, blocked the 
positive anti-hypertrophic actions of IL-33 in a dose-
dependent manner, suggesting that sST2 may act as a 
“decoy receptor” for circulating IL-33. In an in vivo model 
of pressure overload, ST2 knockout mice showed- higher 
myocyte hypertrophy and fibrosis and lower fractional 
shortening than wild-type mice after 4 weeks of aortic 
banding. IL-33 administration preserved wild-type mice 
from the hypertrophic phenotype, but this action was not 
observed in ST2−/− mice, suggesting that IL-33/ST2 
signaling protects against adverse cardiac remodeling in 
vivo [19-20].  
A possible mechanism by which the alteration in ST2 
signaling may lead to tissue fibrosis has been identified by 
Seki and co-workers. IL-33 inhibits cardiomyocyte
Figure 3. Specific production of IL-33, ST2 and sST2 by the different cellular types of the 
cardiovascular compartment. IL-33 is expressed by human adult cardiac myocytes and fibroblasts and 
by human coronary artery smooth muscle cells. The receptor ST2 is predominantly expressed by 
endothelial cells of the cardiac vasculature. Both sST2 and ST2L are induced in cardiomyocytes and 
fibroblasts after biomechanical stress. 
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apoptosis both in vitro and in vivo via suppression of 
caspase-3 activity and increased expression of inhibitor of 
apoptosis proteins (IAP), thus improving cardiac 
contractile function after ischemia/reperfusion myocardial 
injury in rats. The cardioprotective effects of IL-33 were 
abolished in ST2-null mice, demonstrating that IL-33 is 
cardioprotective through ST2 signaling [21]. Moreover, it 
has been demonstrated that the protective role of IL-33 may 
be reduced by endothelin-1, which enhanced the production 
of sST2 and inhibited IL-33 downstream signaling through 
p38 MAP Kinase [22]. 
c. Human model  
In a very recent paper [23], it has been shown that patients 
with HF presented differentially expressed levels of 
ST2/IL-33 as well as conventional inflammatory mediators 
(IL-6, IL-8 and TNFα) in both plasma and cardiac tissue, 
and that these modifications are corrected by mechanical 
unloading through left ventricle assist device (LVAD) 
support. Lower expression of ST2 and IL-33 was found in 
cardiac tissue of patients undergoing LVAD support 
compared to more stable patients undergoing heart 
transplantation on medical therapy only. These data 
suggested a protective effect of ST2/IL-33 pathway in the 
worsening of cardiac function, as previous reported [17, 20-
21]. This cardioprotective action was confirmed by the 
increase in their levels by mechanical unloading after 
LVAD support, possibly due to the reverse remodeling 
process, which was able to restore levels comparable to 
those observed for the heart transplant group of patients.  
Results from this study also provided further insight into 
the role of classic inflammatory mediators in HF [23]. As 
with the IL-33/ST2 pathway, IL-6, IL-8 and TNF-a were 
Figure 4.Theraputic strategies targeting IL-33/ST2 pathway. The IL-33/ST2 pathway may be 
triggered by exogenous administration of IL-33 (1) or by promoting IL-33 release from cardiac 
cells (2). IL-33/ST2 complex could be increased by inhibiting sST2 by therapeutic compounds 
designed to directly stimulate the ST2 (3). Modifications of the intracellular signaling, including 
sequestration of MyD88 by exogenous pharmaco-therapeutics, could represent a possible option 
(4). 
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Table 1. Cardiac diseases in which sST2 circulating 
levels were measured 
Cardiac disease References 
Acute myocardial infarction 29-33, 50 
Acute heart failure 35-37, 44, 48, 50 
Chronic heart failure 38-43, 52-54 
Pleural cardiac effusion 55 
Aortic stenosis 56 
Diastolic dysfunction and diabetes 57 
Coronary bypass and heart surgery 58, 59 
Acute cardiac allograft rejection 60 
Acute Kawasaki disease 61 
low in less stable HF patients and were higher after LVAD 
support up to a level comparable to that of patients directly 
undergoing heart transplantation with only medical therapy. 
In spite of their well-documented role as pro-inflammatory 
cytokines, these molecules showed a negative role in HF 
progression and were positively involved in the reverse 
remodeling process by LVAD, eventually suggesting a 
compensatory effect to the adverse remodeling process of 
HF. Recent studies hypothesized that temporally regulated 
activation and suppression of inflammation may be critical 
for achieving effective cardiac repair, indicating a 
paradoxical role of inflammation in cardiac repair [24].  
A very recent paper demonstrated that in human 
myocardial tissue from hearts of patients undergoing heart 
transplantation, endothelial cells are the main cell type 
expressing both IL-33 as well as its receptor ST2 and that 
IL-33 expression correlates positively with that TNF-α and 
IFN-γ, respectively [19]. 
3. ST2 as therapeutic target 
The results from experimental and clinical studies 
suggest that modulation of the IL-33/ST2 system could 
exert cardioprotective activity in the context of heart 
disease. Thus, strategies that chronically target IL-33/ST2 
signaling should be considered to have potential adverse 
cardiovascular consequences. Moreover, manipulation of 
the IL-33/ST2 pathway is a promising new therapeutic 
approach for treating or preventing various disorders in 
which inflammation is a critical process. To date, several 
approaches have been proved to modulate IL-33/ST2 
signaling, addressing its cardioprotective activity [12] (Fig. 
4). The IL-33/ST2 pathway may be triggered by exogenous 
administration of IL-33 or by promoting IL-33 release from 
cardiac cells. Moreover, IL-33/ST2 complex could be 
increased by inhibiting sST2, the IL-33 decoy receptor, by 
therapeutic compounds designed to directly stimulate the 
ST2. Alternatively, modification of intracellular signaling 
could be a possible option: the cardioprotective effects of 
IL-33 may be reproduced by sequestration of MyD88 by 
exogenous pharmacotherapeutics. Moreover, further study 
is needed in order to explain the possible causal 
relationships between the molecules involved in this 
signaling, such as  nuclear factor-kB (NF-kB), adaptor 
protein 1 (AP-1) or extracellular signal-regulated kinase 
(ERK). These clarifications might be an important step in 
the IL/33/ST2 signaling that is accessible to manipulation.  
However, due to the involvement of the IL-33/ST2 
system in a variety of processes, its manipulation may also 
have negative consequences, resulting in exacerbation of 
inflammatory conditions. Conversely, inhibition of this 
system to regulate these inflammatory conditions could 
result in a worsening of cardiovascular disease. 
4. ST2 as circulating biomarker  
The possibility of using sST2 as a potential biomarker 
for cardiac disease was originally raised in 2002 when it 
was found that sST2 levels were transiently increased in 
peripheral circulation of mice after myocardial infarction 
[17]. Later, it was shown that blood concentrations of sST2 
increase in heart disease and are taken into account as a 
possible prognostic marker [25-27].  
a. sST2 Assay 
The first ELISA for evaluating circulating sST2 in 
serum/plasma was developed in 2000 [25]. To date, three 
main assays have been tested: the MBL ST2 ELISA kit 
(Medical & Biological Laboratories, MA, USA), the 
Human ST2/IL-1 R4 DuoSet® (R&D Systems, MN, USA) 
and the Presage ST2 Assay (Critical Diagnostics, CA, USA) 
[26]. The MBL ST2 assay and the R&D ST2 assay are 
research assays. In 2011, the Presage ST2 Assay received 
the Conformitè Europèenne (CE) Mark and the US FDA 
approved the Presage ST2 Assay for use in assessing the 
prognosis of HF patients [27].  
sST2 concentrations obtained by these three 
commercially available assays are not equal to each other, 
probably due to the different methodological conditions, 
including standards, antibodies, and also reagents and 
buffers [26, 28]. Thus, the direct comparison of the results 
obtained with the three methods is not feasible and the 
superiority of one out of the three assays has yet to be 
demonstrated. Moreover, the three methods should be 
standardized because many methodological aspects should 
be clarified. It is not clear if any of the three methods has a 
calibrator that is correctly quantified and which epitopes 
are detected by the antibodies against sST2 used for the 
three methods. Therefore, it is not known whether primary, 
secondary or tertiary structures of the sST2 protein are 
specifically recognized by the different antibodies used in 
the three assays. Another important issue is related to the 
analytical sensitivity of each methods [26, 28].   
Inflammation & Cell Signaling 2014; 1: e149. doi: 10.14800/ics.149; ©  2014 by Chiara Caselli. 
http://www.smartscitech.com/index.php/ics 
 
Page 7 of 9 
 
b. Clinical relevance 
Several clinical studies in patients with acute myocardial 
infarction or acute coronary syndrome [29-34], in acute and 
chronic HF [35- 43], showed that high sST2 levels are related 
to adverse outcome. Moreover, in HF serial determination 
of sST2 has a prognostic role and could show value in 
biomarker-directed therapy [27, 43, 44]. Conversely, 
determination of sST2 was not useful for the diagnosis of 
acute myocardial infarction or acute coronary syndrome [44-
46] and HF in patients with acute dyspnea [47, 48].  
Compared with cardiac Natriuretic Peptides (ANP, BNP 
or NT-proBNP) that specifically mirror the 
pathophysiological conditions of cardiac stretch, sST2 does 
not completely show this specificity, thus lacking the 
prerequisite for diagnostic purposes. sST2 does not merely 
reflect the condition of cardiac stretch but is also involved 
in other non-cardiac conditions such as inflammation. In 
fact, inflammation is a process simultaneously present in a 
large proportion of patients with heart disease, making 
sST2 a poor diagnostic marker in such a setting. On the 
contrary, as a consequence of the non-specificity of sST2, 
it seems to be a reliable prognostic marker in various 
diseases (Table 1).  
Accordingly, sST2 could be a good prognostic marker in 
patients with negative outcome presenting simultaneously 
HF and inflammatory diseases [27, 49]. Because sST2 
appears to be associated with both inflammation and 
cardiac stretch, it could be a strong and independent 
outcome predictor in this setting. Of note, it is becoming 
evident that sST2 is not only an independent prognostic 
biomarker, but it is also able to provide incremental 
prognostic value outperforming clinical variables and other 
biomarkers. This is a very relevant issue in clinical practice, 
because clinicians currently use diverse clinical 
information, several scoring systems and established 
biomarkers such as cardiac Troponins or Natriuretic 
Peptides for evaluation of patient outcome and 
management [27].  
It was recently shown that baseline cardiac ST2 
positively correlated with its soluble isoform and did not 
show any modification after 1 month of LVAD support [23]. 
These data might confirm the cardiac production of soluble 
sST2, and considering the role of ST2 as a soluble decoy 
receptor for IL-33, could explain the negative prognostic 
value of this biomarker in individuals with HF. Conversely, 
before LVAD implant cardiac IL- 33 was negatively related 
with its plasma concentration and resulted significantly 
decreased after 1 month- compared to its values before 
LVAD support, suggesting a different regulatory 
mechanism for IL-33 [23]. 
Conclusions 
IL-33/ST2 pathway plays an important role in protection 
of cardiac muscle. Furthermore, sST2 is a promising 
biomarker predictive of worse outcome in several 
cardiovascular diseases. Although modulation of the IL-
33/ST2 system is still in its infancy, it may be a unique 
opportunity to quench the inflammatory response after 
cardiac injury. It remains to better understand many aspects 
of IL-33/ST2 downstream intracellular signaling. 
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